Do analysts recommend ATOS or EXOZ?

Atossa Genetics presently has a consensus target price of $24.50, indicating a potential upside of 1,147.45%. Given Atossa Genetics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Atossa Genetics is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atossa Genetics 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ATOS or EXOZ more profitable?

Atossa Genetics' return on equity of -84.91% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets Atossa Genetics N/A -84.91% -72.36% eXoZymes N/A -220.63% -141.26%

Does the media refer more to ATOS or EXOZ?

In the previous week, Atossa Genetics and Atossa Genetics both had 2 articles in the media. Atossa Genetics' average media sentiment score of 1.28 beat eXoZymes' score of 1.19 indicating that Atossa Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atossa Genetics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive eXoZymes 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, CTOR or ATOS?

Citius Oncology is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Citius Oncology N/A N/A -$24.76M -$0.47 N/A Atossa Genetics N/A N/A -$34.77M -$3.21 N/A

Is CTOR or ATOS more profitable?

Atossa Genetics' return on equity of -84.91% beat Citius Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Citius Oncology N/A -99.47% -42.16% Atossa Genetics N/A -84.91% -72.36%

Does the media refer more to CTOR or ATOS?

In the previous week, Citius Oncology and Citius Oncology both had 2 articles in the media. Citius Oncology's average media sentiment score of 1.32 beat Atossa Genetics' score of 1.28 indicating that Citius Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Citius Oncology 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atossa Genetics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ATOS or MCRB more profitable?

Atossa Genetics' return on equity of -84.91% beat Seres Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Atossa Genetics N/A -84.91% -72.36% Seres Therapeutics N/A -130.29% -35.35%

Does the media favor ATOS or MCRB?

In the previous week, Seres Therapeutics had 3 more articles in the media than Atossa Genetics. MarketBeat recorded 5 mentions for Seres Therapeutics and 2 mentions for Atossa Genetics. Atossa Genetics' average media sentiment score of 1.28 beat Seres Therapeutics' score of 1.03 indicating that Atossa Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atossa Genetics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Seres Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ATOS or MNOV?

In the previous week, MediciNova had 3 more articles in the media than Atossa Genetics. MarketBeat recorded 5 mentions for MediciNova and 2 mentions for Atossa Genetics. Atossa Genetics' average media sentiment score of 1.28 beat MediciNova's score of 0.52 indicating that Atossa Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atossa Genetics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MediciNova 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate BYSI or ATOS?

Atossa Genetics has a consensus price target of $24.50, suggesting a potential upside of 1,147.45%. Given Atossa Genetics' stronger consensus rating and higher probable upside, analysts plainly believe Atossa Genetics is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Atossa Genetics 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is BYSI or ATOS more profitable?

BeyondSpring's return on equity of 0.00% beat Atossa Genetics' return on equity. Company Net Margins Return on Equity Return on Assets BeyondSpring N/A N/A -14.00% Atossa Genetics N/A -84.91% -72.36%

Atossa Genetics (ATOS) Competitors

$1.96 +0.03 (+1.76%)

As of 10:32 AM Eastern

Compare

ATOS vs. EXOZ, CTOR, MCRB, MNOV, and BYSI

Should you buy Atossa Genetics stock or one of its competitors? MarketBeat compares Atossa Genetics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Atossa Genetics include eXoZymes (EXOZ), Citius Oncology (CTOR), Seres Therapeutics (MCRB), MediciNova (MNOV), and BeyondSpring (BYSI). These companies are all part of the "pharmaceutical products" industry.

How does Atossa Genetics compare to eXoZymes?

Atossa Genetics (NASDAQ:ATOS) and eXoZymes (NASDAQ:EXOZ) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

Atossa Genetics has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market. Comparatively, eXoZymes has a beta of 2.65, indicating that its share price is 165% more volatile than the broader market.

Atossa Genetics presently has a consensus target price of $24.50, indicating a potential upside of 1,147.45%. Given Atossa Genetics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Atossa Genetics is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

12.7% of Atossa Genetics shares are owned by institutional investors. 9.8% of Atossa Genetics shares are owned by insiders. Comparatively, 72.4% of eXoZymes shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

eXoZymes has higher revenue and earnings than Atossa Genetics. eXoZymes is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$34.77M	-$3.21	N/A
eXoZymes	$70K	995.79	-$9.16M	-$1.14	N/A

Atossa Genetics' return on equity of -84.91% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-84.91%	-72.36%
eXoZymes	N/A	-220.63%	-141.26%

In the previous week, Atossa Genetics and Atossa Genetics both had 2 articles in the media. Atossa Genetics' average media sentiment score of 1.28 beat eXoZymes' score of 1.19 indicating that Atossa Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atossa Genetics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
eXoZymes	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Atossa Genetics beats eXoZymes on 8 of the 13 factors compared between the two stocks.

How does Atossa Genetics compare to Citius Oncology?

Citius Oncology (NASDAQ:CTOR) and Atossa Genetics (NASDAQ:ATOS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

Atossa Genetics' return on equity of -84.91% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-99.47%	-42.16%
Atossa Genetics	N/A	-84.91%	-72.36%

Citius Oncology currently has a consensus price target of $6.00, indicating a potential upside of 782.35%. Atossa Genetics has a consensus price target of $24.50, indicating a potential upside of 1,147.45%. Given Atossa Genetics' higher probable upside, analysts clearly believe Atossa Genetics is more favorable than Citius Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Citius Oncology is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A
Atossa Genetics	N/A	N/A	-$34.77M	-$3.21	N/A

In the previous week, Citius Oncology and Citius Oncology both had 2 articles in the media. Citius Oncology's average media sentiment score of 1.32 beat Atossa Genetics' score of 1.28 indicating that Citius Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Citius Oncology	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atossa Genetics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

70.5% of Citius Oncology shares are owned by institutional investors. Comparatively, 12.7% of Atossa Genetics shares are owned by institutional investors. 9.8% of Citius Oncology shares are owned by insiders. Comparatively, 9.8% of Atossa Genetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Citius Oncology has a beta of 3.41, suggesting that its stock price is 241% more volatile than the broader market. Comparatively, Atossa Genetics has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market.

Summary

Citius Oncology beats Atossa Genetics on 7 of the 10 factors compared between the two stocks.

How does Atossa Genetics compare to Seres Therapeutics?

Atossa Genetics (NASDAQ:ATOS) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

Seres Therapeutics has higher revenue and earnings than Atossa Genetics. Seres Therapeutics is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$34.77M	-$3.21	N/A
Seres Therapeutics	$790K	95.70	$5.70M	-$5.17	N/A

Atossa Genetics' return on equity of -84.91% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-84.91%	-72.36%
Seres Therapeutics	N/A	-130.29%	-35.35%

12.7% of Atossa Genetics shares are owned by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are owned by institutional investors. 9.8% of Atossa Genetics shares are owned by company insiders. Comparatively, 5.2% of Seres Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Atossa Genetics currently has a consensus price target of $24.50, indicating a potential upside of 1,147.45%. Seres Therapeutics has a consensus price target of $17.00, indicating a potential upside of 117.67%. Given Atossa Genetics' higher probable upside, equities analysts plainly believe Atossa Genetics is more favorable than Seres Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Seres Therapeutics had 3 more articles in the media than Atossa Genetics. MarketBeat recorded 5 mentions for Seres Therapeutics and 2 mentions for Atossa Genetics. Atossa Genetics' average media sentiment score of 1.28 beat Seres Therapeutics' score of 1.03 indicating that Atossa Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atossa Genetics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Seres Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Atossa Genetics has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market. Comparatively, Seres Therapeutics has a beta of 0.13, indicating that its stock price is 87% less volatile than the broader market.

Summary

Atossa Genetics beats Seres Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Atossa Genetics compare to MediciNova?

Atossa Genetics (NASDAQ:ATOS) and MediciNova (NASDAQ:MNOV) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

MediciNova has higher revenue and earnings than Atossa Genetics. MediciNova is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$34.77M	-$3.21	N/A
MediciNova	$410K	173.47	-$12M	-$0.23	N/A

Atossa Genetics has a net margin of 0.00% compared to MediciNova's net margin of -1,962.98%. MediciNova's return on equity of -27.28% beat Atossa Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-84.91%	-72.36%
MediciNova	-1,962.98%	-27.28%	-25.24%

12.7% of Atossa Genetics shares are held by institutional investors. Comparatively, 9.9% of MediciNova shares are held by institutional investors. 9.8% of Atossa Genetics shares are held by company insiders. Comparatively, 14.0% of MediciNova shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, MediciNova had 3 more articles in the media than Atossa Genetics. MarketBeat recorded 5 mentions for MediciNova and 2 mentions for Atossa Genetics. Atossa Genetics' average media sentiment score of 1.28 beat MediciNova's score of 0.52 indicating that Atossa Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atossa Genetics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MediciNova	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Atossa Genetics presently has a consensus price target of $24.50, indicating a potential upside of 1,147.45%. MediciNova has a consensus price target of $8.33, indicating a potential upside of 476.70%. Given Atossa Genetics' higher possible upside, equities analysts clearly believe Atossa Genetics is more favorable than MediciNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Atossa Genetics has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market. Comparatively, MediciNova has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market.

Summary

MediciNova beats Atossa Genetics on 10 of the 16 factors compared between the two stocks.

How does Atossa Genetics compare to BeyondSpring?

BeyondSpring (NASDAQ:BYSI) and Atossa Genetics (NASDAQ:ATOS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.

BeyondSpring has a beta of 0.43, indicating that its stock price is 57% less volatile than the broader market. Comparatively, Atossa Genetics has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market.

40.3% of BeyondSpring shares are held by institutional investors. Comparatively, 12.7% of Atossa Genetics shares are held by institutional investors. 29.3% of BeyondSpring shares are held by insiders. Comparatively, 9.8% of Atossa Genetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

BeyondSpring's return on equity of 0.00% beat Atossa Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeyondSpring	N/A	N/A	-14.00%
Atossa Genetics	N/A	-84.91%	-72.36%

In the previous week, Atossa Genetics had 1 more articles in the media than BeyondSpring. MarketBeat recorded 2 mentions for Atossa Genetics and 1 mentions for BeyondSpring. BeyondSpring's average media sentiment score of 1.87 beat Atossa Genetics' score of 1.28 indicating that BeyondSpring is being referred to more favorably in the media.

Company	Overall Sentiment
BeyondSpring	Very Positive
Atossa Genetics	Positive

Atossa Genetics has a consensus price target of $24.50, suggesting a potential upside of 1,147.45%. Given Atossa Genetics' stronger consensus rating and higher probable upside, analysts plainly believe Atossa Genetics is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

BeyondSpring has higher revenue and earnings than Atossa Genetics. BeyondSpring is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring	$1.75M	40.18	-$1.01M	-$0.14	N/A
Atossa Genetics	N/A	N/A	-$34.77M	-$3.21	N/A

Summary

BeyondSpring beats Atossa Genetics on 8 of the 14 factors compared between the two stocks.

Get Atossa Genetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATOS vs. The Competition

Export

Metric	Atossa Genetics	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$16.88M	$7.30B	$6.80B	$12.55B
Dividend Yield	N/A	1.25%	2.66%	6.16%
P/E Ratio	-0.61	50.95	27.42	25.27
Price / Sales	N/A	80.91	542.60	102.53
Price / Cash	N/A	26.23	48.53	58.59
Price / Book	0.43	7.47	11.00	6.57
Net Income	-$34.77M	$159.19M	$3.57B	$336.82M
7 Day Performance	12.23%	0.43%	2.69%	2.31%
1 Month Performance	-61.57%	-3.66%	1.85%	-0.12%
1 Year Performance	-84.11%	5.19%	36.85%	30.30%

Atossa Genetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATOS Atossa Genetics	3.0834 of 5 stars	$1.96 +1.8%	$24.50 +1,147.5%	-84.5%	$16.88M	N/A	N/A	8	News Coverage Positive News
EXOZ eXoZymes	0.9012 of 5 stars	$7.91 -3.4%	N/A	-14.7%	$67.03M	N/A	N/A	29	Positive News
CTOR Citius Oncology	2.6493 of 5 stars	$0.72 +1.7%	$6.00 +733.3%	-85.1%	$66.95M	N/A	N/A	N/A	News Coverage Positive News
MCRB Seres Therapeutics	3.9536 of 5 stars	$6.78 +2.7%	$17.00 +150.9%	-29.0%	$66.09M	$1.15M	N/A	330	Positive News Short Interest Decrease
MNOV MediciNova	3.2502 of 5 stars	$1.36 +4.3%	$8.33 +514.6%	+0.8%	$65.71M	$410K	N/A	10	News Coverage Short Interest Decrease Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATOS) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Atossa Genetics (ATOS) Competitors

ATOS vs. EXOZ, CTOR, MCRB, MNOV, and BYSI

How does Atossa Genetics compare to eXoZymes?

Summary

How does Atossa Genetics compare to Citius Oncology?

Summary

How does Atossa Genetics compare to Seres Therapeutics?

Summary

How does Atossa Genetics compare to MediciNova?

Summary

How does Atossa Genetics compare to BeyondSpring?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATOS vs. The Competition

Atossa Genetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Atossa Genetics (ATOS) Competitors

ATOS vs. EXOZ, CTOR, MCRB, MNOV, and BYSI

How does Atossa Genetics compare to eXoZymes?

Which has more volatility and risk, ATOS or EXOZ?

Do analysts recommend ATOS or EXOZ?

Do institutionals and insiders believe in ATOS or EXOZ?

Which has higher earnings & valuation, ATOS or EXOZ?

Is ATOS or EXOZ more profitable?

Does the media refer more to ATOS or EXOZ?

Summary

How does Atossa Genetics compare to Citius Oncology?

Is CTOR or ATOS more profitable?

Do analysts recommend CTOR or ATOS?

Which has preferable earnings & valuation, CTOR or ATOS?

Does the media refer more to CTOR or ATOS?

Do institutionals and insiders believe in CTOR or ATOS?

Which has more risk & volatility, CTOR or ATOS?

Summary

How does Atossa Genetics compare to Seres Therapeutics?

Which has higher valuation and earnings, ATOS or MCRB?

Is ATOS or MCRB more profitable?

Do insiders & institutionals have more ownership in ATOS or MCRB?

Do analysts recommend ATOS or MCRB?

Does the media favor ATOS or MCRB?

Which has more volatility and risk, ATOS or MCRB?

Summary

How does Atossa Genetics compare to MediciNova?

Which has stronger valuation and earnings, ATOS or MNOV?

Is ATOS or MNOV more profitable?

Do institutionals & insiders have more ownership in ATOS or MNOV?

Does the media favor ATOS or MNOV?

Do analysts rate ATOS or MNOV?

Which has more volatility and risk, ATOS or MNOV?

Summary

How does Atossa Genetics compare to BeyondSpring?

Which has more risk and volatility, BYSI or ATOS?

Do insiders and institutionals have more ownership in BYSI or ATOS?

Is BYSI or ATOS more profitable?

Does the media prefer BYSI or ATOS?

Do analysts rate BYSI or ATOS?

Which has stronger earnings and valuation, BYSI or ATOS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATOS vs. The Competition

Atossa Genetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools